GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Shareholders supporting PHP's bid for Assura in finance news - Global Banking & Finance Review
The image depicts a financial market scene highlighting Assura shareholders' support for PHP's takeover bid, emphasizing investor confidence in UK finance amid private equity competition.
Finance

British cancer drug developer Ellipses Pharma considers London listing

Published by Global Banking & Finance Review

Posted on November 18, 2026

2 min read

· Last updated: November 18, 2026

Add as preferred source on Google

British Cancer Drug Developer Ellipses Pharma Plans London Listing by 2027

Ellipses Pharma's London Listing Plans and Market Impact

(Corrects typographical error in headline)

Company Overview and Pipeline

Nov 18 (Reuters) - British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a London listing through a deal with  special purpose acquisition company Wolfram Resources. 

Drug Development Focus

• Established in 2017, Ellipses Pharma's pipeline includes trials for drugs to treat non-small cell lung cancer and breast cancer

Listing Strategy and Timeline

Reverse Takeover Details

• The company plans to list its shares on the London bourse following a reverse takeover by shell company Wolfram Resources, whose terms are yet to be agreed

Market Implications

• The floatation will provide a much-needed boost to the UK's market which has seen an exodus from companies eyeing higher valuations in markets like the United States

Transaction Timeline

• Ellipses Pharma said it is targeting completing the transaction by early 2027

Equity Fundraise

• The firm also expects an equity fundraise in conjunction with the deal

Capital Raising Benefits

• Listing through a reverse takeover process will enable the company to raise additional capital from public company investors, founder and chair Chris Evans said

Reporting Credits

(Reporting by Simone Lobo in Bengaluru; Editing by Nivedita Bhattacharjee)

Key Takeaways

  • Ellipses has signed a non‑binding MoU with Wolfram Resources for a reverse takeover and Main Market relisting in London, with due diligence underway and a goal to complete by early 2027 (tradingview.com).
  • The company's pipeline includes Phase 2 assets EP0031 (lunbotinib) for RET‑altered non‑small cell lung cancer and EP0062 (vosilasarm) for ER+/HER2– breast cancer, backed by a Scientific Advisory Group of over 300 oncology experts (tradingview.com).
  • The transaction aims to inject much‑needed capital into the UK biotech market, with Ellipses planning an equity fundraise alongside the listing to fuel its drug development programmes (tradingview.com).

References

Frequently Asked Questions

What is Ellipses Pharma planning regarding the London Stock Exchange?
Ellipses Pharma is exploring a London listing via a reverse takeover deal with Wolfram Resources.
When does Ellipses Pharma aim to complete its London listing?
Ellipses Pharma targets completing the transaction by early 2027.
What is the purpose of the reverse takeover with Wolfram Resources?
The reverse takeover enables Ellipses Pharma to list on the London bourse and raise additional capital.
What types of drugs is Ellipses Pharma developing?
Ellipses Pharma's pipeline includes drugs for non-small cell lung cancer and breast cancer.
Why is the Ellipses Pharma London listing significant for the UK market?
It is expected to boost the UK market, which has seen companies seek higher valuations elsewhere.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category